Drug intelligence / Profile preview

magnesium + pyridoxine (OMNIFARMA)

Development stage
Approved
Lead developer
OMNIFARMA KIEV
Modality
Small Molecules
Administration
Oral
01

Overview

Magnel is a dietary supplement developed by Omnifarma, primarily indicated for the prevention and treatment of magnesium and vitamin B6 deficiencies. It contains a combination of magnesium (typically as magnesium citrate) and pyridoxine hydrochloride (Vitamin B6). Magnesium is a vital intracellular cation involved in over 300 metabolic processes, including ATP production, muscle contraction, and neuronal excitability. Pyridoxine acts as a coenzyme in the metabolism of amino acids and neurotransmitters and is known to synergistically enhance the intestinal absorption and cellular retention of magnesium. This combination is frequently used to alleviate symptoms of deficiency such as irritability, sleep disturbances, muscle cramps, and fatigue.

Brand names
MagnelМагнель
Other names
magnesium + vitamin B6magnesium + pyridoxine hydrochloride
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on magnesium + pyridoxine (OMNIFARMA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on magnesium + pyridoxine (OMNIFARMA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call